One year after the approval of Lecanemab in Japan

Consistent with prior evidence, Asian patients tend to have less ARIA side effects. Due to the high demand of Lecanemab treatment, it is necessary to promptly refer patients to continuous administration facilities after the initial 6 months of administration.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_100084
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

One year after the approval of Lecanemab in Japan

Yuki Kujuro
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

One year after the approval of Lecanemab in Japan

Yuki Kujuro
article en

Abstract

Consistent with prior evidence, Asian patients tend to have less ARIA side effects. Due to the high demand of Lecanemab treatment, it is necessary to promptly refer patients to continuous administration facilities after the initial 6 months of administration.

Alzheimer s & DementiaVol. 21(S5)
Tachikawa Hospital (JP)
Openalex Percentile: Top 33%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

One year after the approval of Lecanemab in Japan — Yuki Kujuro · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS